This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Jamie Rich
Director, Technology, ADC Therapeutic Development at Zymeworks


Jamie Rich is Senior Director of Technology in the ADC Therapeutic Development Department at Zymeworks, where his team focuses on discovery and pipeline application of new ADC technologies. Dr. Rich is a co-inventor of multiple technologies and assets associated with Zymeworks’ ZymeLink™, preCYSion, and Topoisomerase 1 inhibitor ADC platforms. His group is currently interested in the design principles which enable antibody drug conjugates to improve upon the efficacy of small molecule chemotherapies in some instances.

Agenda Sessions

  • Reconsidering Some Commonly Held Beliefs About Antibody Drug Conjugates (ADCs)